MEDIMMUNE, ASTRAZENECA’S BIOLOGICS ARM, AND NGM BIOPHARMACEUTICALS ANNOUNCE AGREEMENT TO DISCOVER AND DEVELOP THERAPIES FOR DIABETES AND OBESITY

Nyheten uppdaterades 2013-06-17 8:19

today announced that , its global biologics research and development arm, and Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialise novel therapeutics from ’s enteroendocrine cell (EEC) programme for the of type 2 diabetes and .

represent less than 1% of all gastrointestinal (GI) cells,…

Källa: Mynewsdesk news release

Lämna gärna en kommentar